{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:16:16Z","timestamp":1772075776496,"version":"3.50.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,21]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Fabry disease (FD) is a rare, inherited disease lysosomal storage disorder caused by the lack of an alpha-galactosidase enzyme. This genetic disease can affect both men and women. The understanding of FD is very important as this condition can be effectively treated. For women who may exhibit normal residual enzyme activity, the diagnosis is more challenging.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation:<\/jats:title>\n            <jats:p>Herein, we reported on a case of IgA nephropathy and renal disease that mimicked FD in a female patient. The presence of zebra bodies in the cytoplasm of glomerular podocytes is widely accepted as a hallmark pathological manifestation of FD. In the present case, renal biopsy analysis revealed the presence of zebra bodies; however, genetic testing indicated that the patient did not have FD. The mechanisms and causes of zebra body formation remained unclear in the present case. However, the patient responded well to treatment with an angiotensin receptor blocker.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The reported findings can be useful for the differential diagnosis of FD and renal diseases in the future. Our results also highlight the clinical significance of zebra bodies in renal disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000031060","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T19:01:52Z","timestamp":1666638112000},"page":"e31060","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["IgA nephropathy with mimicking Fabry disease: A case report and literature review"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1222-2298","authenticated-orcid":false,"given":"Liping","family":"Sun","sequence":"first","affiliation":[{"name":"Key Renal Laboratory of Shenzhen, Shenzhen, China"},{"name":"Department of Nephrology, Shenzhen People\u2019s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zi","sequence":"additional","affiliation":[{"name":"Key Renal Laboratory of Shenzhen, Shenzhen, China"},{"name":"Department of Nephrology, Shenzhen People\u2019s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Renal Laboratory of Shenzhen, Shenzhen, China"},{"name":"Department of Nephrology, Shenzhen People\u2019s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinzhou","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Renal Laboratory of Shenzhen, Shenzhen, China"},{"name":"Department of Nephrology, Shenzhen People\u2019s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease.","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes.","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol Genet Metab"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00431-017-2950-8","article-title":"Newborn screening for Fabry disease in the north-west of Spain.","volume":"176","author":"Colon","year":"2017","journal-title":"Eur J Pediatr"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis.","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol Genet Metab"},{"key":"R6-20250504","first-page":"83","article-title":"Uncertain diagnosis of Fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up.","volume":"17","author":"van der Tol","year":"2014","journal-title":"JIMD Rep"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.kint.2018.02.003","article-title":"Hydroxychloroquine-induced mimic of renal Fabry disease.","volume":"94","author":"Sperati","year":"2018","journal-title":"Kidney Int"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1053\/j.ajkd.2006.05.034","article-title":"Iatrogenic phospholipidosis mimicking Fabry disease.","volume":"48","author":"Bracamonte","year":"2006","journal-title":"Am J Kidney Diseases"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e009052","DOI":"10.1161\/JAHA.118.009052","article-title":"Immune-mediated myocarditis in Fabry disease cardiomyopathy.","volume":"7","author":"Frustaci","year":"2018","journal-title":"J Am Heart Association"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5414\/CN108986","article-title":"Clinical and pathological characteristics of Fabry disease combined with IgA nephropathy in Chinese patients.","volume":"87","author":"Yang","year":"2017","journal-title":"Clin Nephrol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.revmed.2020.08.019","article-title":"[Fabry disease: a review].","volume":"42","author":"Michaud","year":"2021","journal-title":"Rev Med Interne"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2215\/CJN.09480819","article-title":"The changing landscape of Fabry disease.","volume":"15","author":"Svarstad","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat.","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/1566523218666180404161315","article-title":"Genetics and gene therapy of Anderson-Fabry disease.","volume":"18","author":"Simonetta","year":"2018","journal-title":"Curr Gene Ther"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/cge.13694","article-title":"Diagnostic strategy for females suspected of Fabry disease.","volume":"97","author":"Balendran","year":"2020","journal-title":"Clin Genet"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and how to diagnose Fabry disease in clinical pratice.","volume":"360","author":"Michaud","year":"2020","journal-title":"Am J Med Sci"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5414\/CNCS110131","article-title":"Post-transplant de-novo renal phospholipidosis in a kidney transplant recipient: Fabry disease or something else?","volume":"8","author":"Naseer","year":"2020","journal-title":"Clin Nephrol.Case Stud"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000492157","article-title":"Clinic-pathologic features and renal outcome of Fabry disease: data from a Chinese cohort.","volume":"48","author":"Zhang","year":"2018","journal-title":"Am J Nephrol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:41:24Z","timestamp":1746333684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":17,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031060","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]}}}